TY - JOUR
TI - Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series
AU - Bamias, A.
AU - Hegele, A.
AU - Medioni, J.
AU - Castellano, D.
AU - Doni, L.
AU - Passalacqua, R.
AU - Zagouri, F.
AU - Tzannis, K.
AU - Hussain, S.
AU - Ullen, A.
JO - Critical Reviews in Oncology/Hematology
PY - 2019
VL - 140
TODO - null
SP - 80-87
PB - Elsevier Ireland Ltd
SN - 1040-8428
TODO - 10.1016/j.critrevonc.2019.05.006
TODO - vinflunine;  antineoplastic agent;  platinum derivative;  vinblastine;  vinflunine, anemia;  asthenia;  cancer prognosis;  cancer recurrence;  constipation;  drug efficacy;  drug response;  drug safety;  drug utilization;  fatigue;  fever;  human;  meta analysis;  metastasis;  nausea and vomiting;  neutropenia;  overall survival;  progression free survival;  Review;  systematic review;  thrombocytopenia;  transitional cell carcinoma;  aged;  constipation;  Europe;  fatigue;  female;  male;  metastasis;  middle aged;  nausea;  pathology;  recurrent disease;  treatment outcome;  urinary tract tumor;  vomiting, Aged;  Antineoplastic Combined Chemotherapy Protocols;  Constipation;  Europe;  Fatigue;  Female;  Humans;  Male;  Middle Aged;  Nausea;  Neoplasm Metastasis;  Platinum Compounds;  Recurrence;  Treatment Outcome;  Urologic Neoplasms;  Vinblastine;  Vomiting
TODO - Background: Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. Methods: We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. Results: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fatigue (41%), constipation (39%), nausea/vomiting (25%), and most prevalent Grade 3–4 toxicities were neutropenia (13%), anaemia (9%), fatigue (8%). Median OS was comparable to results reported in recent randomized studies. Conclusion: Our findings confirm the efficacy and safety of VFL in an unselected population and support the use of VFL in the changing treatment paradigm of relapsed mUC. © 2019 Elsevier B.V.
ER -